Have a personal or library account? Click to login
Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma Cover

Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma

Open Access
|May 2019

References

  1. 1. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK: Liver transplantation: immunosuppression and oncology. Current opinion in organ transplantation 2014, 19(3):253.10.1097/MOT.0000000000000069
  2. 2. Gallego-Melcon S, Sanchez de Toledo J, Martinez V, Moraga F, Iglesias J, Ruiz C, Allende E: Non-Hodgkin’s lymphoma after liver transplantation: response to chemotherapy. Med Pediatr Oncol 1996, 27(3):156-159.10.1002/(SICI)1096-911X(199609)27:3<;156::AID-MPO4>3.0.CO;2-D
  3. 3. Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martinez- Maza O, Hussain SK, Yang J et al: Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer 2013, 109(1):280-288.10.1038/bjc.2013.294
  4. 4. Taylor AL, Marcus R, Bradley JA: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Critical reviews in oncology/ hematology 2005, 56(1):155-167.10.1016/j.critrevonc.2005.03.015
  5. 5. Huang Q, Yang T, Jin X, Ni X, Qi H, Yan Z: Remission of late-onset post-heart transplantation lymphoproliferative disorder following treatment with rituximab and modified mini-CHOP chemotherapy: A case report. Experimental and therapeutic medicine 2016, 12(1):262-266.10.3892/etm.2016.3310
  6. 6. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117(19):5019-5032.10.1182/blood-2011-01-293050
  7. 7. Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G, Fernberg P, Sundstrom C, Pauksens K, Enblad G: A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol 2014, 53(5):669-679.10.3109/0284186X.2013.844853
  8. 8. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG et al: Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005, 23(30):7574-7582.10.1200/JCO.2005.01.0934
  9. 9. Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF et al: The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. Am J Transplant 2015, 15(10):2665-2673.10.1111/ajt.13324
  10. 10. Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I et al: Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 2013, 13(5):1305-1316.2348947410.1111/ajt.12196
  11. 11. van Leeuwen MT, Grulich AE, Webster AC, Mc- Credie MR, Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM: Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009, 114(3):630-637.10.1182/blood-2009-02-202507
  12. 12. Opelz G, Dohler B: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4(2):222-230.10.1046/j.1600-6143.2003.00325.x
  13. 13. Engels EA, Pfeiffer RM, Fraumeni JF, Jr., Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306(17):1891-1901.10.1001/jama.2011.1592
  14. 14. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA: Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011, 86(2):206-209.10.1002/ajh.21911
  15. 15. Dierickx D, Habermann TM: Post-transplantation lymphoproliferative disorders in adults. New England Journal of Medicine 2018, 378(6):549-562.10.1056/NEJMra1702693
  16. 16. Khedmat H, Taheri S: Lymphoproliferative disorders in pediatric liver allograft recipients: a review of 212 cases. Hematology/oncology and stem cell therapy 2012, 5(2):84-90.10.5144/1658-3876.2012.84
  17. 17. Ito K, Siegelman ES, Stolpen AH, Mitchell DG: MR imaging of complications after liver transplantation. American Journal of Roentgenology 2000, 175(4):1145-1149.10.2214/ajr.175.4.1751145
  18. 18. Geissler EK, Schlitt HJ: Immunosuppression for liver transplantation. Gut 2009, 58(3):452-463.10.1136/gut.2008.163527
  19. 19. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gu rusamy KS: Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev 2017, 3:CD011639.10.1002/14651858.CD011639.pub2
  20. 20. Al-Mansour Z, Nelson BP, Evens AM: Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Current hematologic malignancy reports 2013, 8(3):173-183.10.1007/s11899-013-0162-5
  21. 21. Cockfield S: Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transplant infectious disease 2001, 3(2):70-78.10.1034/j.1399-3062.2001.003002070.x
DOI: https://doi.org/10.2478/prilozi-2019-0005 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Language: English
Page range: 67 - 71
Published on: May 31, 2019
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2019 Kalina Grivcheva Stardelova, Aleksandar Stojanovik, Rozalinda Popova Jovanovska, Sonja Stavrik, Magdalena Dimitrova, Neda Milevska Kostova, Vladimir Serafimoski, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.